<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03900390</url>
  </required_header>
  <id_info>
    <org_study_id>FirstSunYetSen118</org_study_id>
    <nct_id>NCT03900390</nct_id>
  </id_info>
  <brief_title>The Study of Potency of Cross-preconditioning to Prevent Ischemic-reperfusion Injury for Heart Transplantation Recipient</brief_title>
  <official_title>The Study of Potency of Cross-preconditioning to Prevent Ischemic-reperfusion Injury for Heart Transplantation Recipient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mengya Liang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In recent years, a large number of studies confirmed the protective effect of ischemic
      preconditioning on myocardium against ischemia/reperfusion injury, but the clinical data of
      the effectiveness of ischemic preconditioning in heart transplantation is still missing.
      Inspired by the promising data of ischemic preconditioning from the previous reports, the
      investigators firstly introduce a novel method of cross ischemic preconditioning technique to
      prevent ischemia/reperfusion injury to heart transplant recipients.

      This study will evaluate whether this cross-preconditioning technique would attenuate
      ischemia/ reperfusion injury to the heart transplant recipients, reduce Intensive Care
      Unit(ICU) and total hospitalization stays and the incidence of cardiovascular adverse events
      and improve the long-term survival outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receiving heart transplantation are randomly assigned into the cross ischemic
      preconditioning (CICP) intervention group and the control group. (the Statistical Analysis
      System (SAS) software was used to generate a random number table and randomly divided into
      two groups). After the establishment of the cardiopulmonary bypass, the ascending aorta of
      the CICP group will be crossclamped 2 minutes, separated by a 3-minute rest interval, and
      repeated successively on 2 occasions.

      The recipients in the control group are to undergo routine cardiopulmonary bypass procedure
      of heart transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2017</start_date>
  <completion_date type="Anticipated">July 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 7, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum troponin T/ creatine kinase-MB level</measure>
    <time_frame>3days</time_frame>
    <description>troponin T/ creatine kinase-MB at definitive time points ( baseline, crossclamping, reperfusion, 6,24,48 and 72 hours postoperatively)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with major adverse cardiacand cerebrovascular events (MACCE) in one year postoperatively</measure>
    <time_frame>1year</time_frame>
    <description>MACCE include death from cardiovascular causes, nonfatal myocardial infarction, coronary revascularization, or strok</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>inotrope score</measure>
    <time_frame>3days</time_frame>
    <description>calculated from the maximum dose of the individual inotropic agents administered in the first 3 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum creatinine level</measure>
    <time_frame>3days</time_frame>
    <description>grade 1, 2, or 3 acute kidney injury within 72 hours after surgery (assessed on the basis of the increase in the serum creatinine level according to the International Kidney Disease: Improving Global Outcomes classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU time</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>duration of stay in the intensive care unit and hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk test</measure>
    <time_frame>2weeks</time_frame>
    <description>distance on the 6-minute walk test two weeks after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Ischemic Preconditioning</condition>
  <arm_group>
    <arm_group_label>Cross Ischemic Preconditioning Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the ascending aorta of the CIP group will be crossclamped to cease the blood supply for 2 minutes, separated by a 3-minute rest interval, and repeated successively on 2 occasions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The recipients in the control group are to undergo routine cardiopulmonary bypass procedure of heart transplantation without Ischemic Preconditioning manoeuvre.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cross-preconditioning</intervention_name>
    <description>After the establishment of the cardiopulmonary bypass, the ascending aorta of the CICP group will be crossclamped 2 minutes, separated by a 3-minute rest interval, and repeated successively on 2 occasions.</description>
    <arm_group_label>Cross Ischemic Preconditioning Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who underwent heart transplantationï¼›

          2. Signed informed consent.

        Exclusion Criteria:

          1. Systemic active infection;

          2. Refractory respiratory failure or renal failure;

          3. Severe systemic diseases with limited survival time.

          4. ABO blood groups incompatibility

          5. positive serum HIV antibody;

          6. drug or alcohol abusing;

          7. Mentally ill;

          8. Recent history of severe pulmonary embolism

          9. Have not signed informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhongkai Wu</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mengya Liang</last_name>
    <phone>13560172190</phone>
    <email>infisdsums@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huayang Li</last_name>
    <phone>18819461186</phone>
    <email>1483409914@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first affiliated hospital of sun yat-sen university</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongkai Wu</last_name>
      <phone>13602897178</phone>
      <email>wuzhk@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>March 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <last_update_submitted>March 30, 2019</last_update_submitted>
  <last_update_submitted_qc>March 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Mengya Liang</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>heart transplantation</keyword>
  <keyword>ischemia-reperfusion injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

